Funding drought: how can biotech and biopharma keep trials running?

It’s widely known in the industry that private investment in biotech and biopharma has been down in recent years. Whilst there was an uptick in biotech and biopharma funding in 2024, this was primarily in early-stage companies, meaning those who missed out during the funding drought continue to be left behind.

In lieu of private funding, biotech and biopharma fell back on government-led funding schemes. However, some of these schemes have been paused or slashed amid global political changes.